<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03354507</url>
  </required_header>
  <id_info>
    <org_study_id>1137</org_study_id>
    <nct_id>NCT03354507</nct_id>
  </id_info>
  <brief_title>Use of Sodium Bicarbonate in Patients Treated With Topiramate</brief_title>
  <official_title>Use of Sodium Bicarbonate to Alkalinize Serum/Urine in Pediatric Patients Treated With Topiramate (Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of oral sodium bicarbonate therapy on renal tubular acidosis in epilepsy patients
      taking topiramate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children on topiramate are at a risk of renal tubular acidosis and subsequent development of
      renal stones. Sodium bicarbonate has been shown to reduce renal tubular acidosis in other
      populations. To date, no data exist on the efficacy of correction of renal tubular acidosis
      in pediatric patients on topiramate. We are proposing to investigate the efficacy of 4 weeks
      of oral sodium bicarbonate therapy to reduce tubular acidosis in patients on topiramate.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in measured urine parameters</measure>
    <time_frame>Baseline, then at 4 weeks</time_frame>
    <description>Spot urine sample will be tested for calcium, creatinine and citrate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in measured blood parameters.</measure>
    <time_frame>Baseline, then at 4 weeks</time_frame>
    <description>sodium, potassium, chloride, calcium, magnesium, phosphate, bicarbonate, alkaline phosphatase, urea, creatinine, venous blood gas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in frequency of seizures.</measure>
    <time_frame>Baseline, then at 4 weeks</time_frame>
    <description>Changes in seizure entries in seizure diary</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Epilepsy</condition>
  <condition>Metabolic Acidosis</condition>
  <condition>Tubular Acidosis; Renal</condition>
  <arm_group>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive sodium bicarbonate for 4 weeks, based on pre-calculated weight based doses. Patients are selected if they have metabolic acidosis at baseline.
&lt; 24 kg : 1/4 teaspoon bid. 24 - 42 kg : 1/2 teaspoon bid. &gt; 42kg : 3/4 teaspoon bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive treatment if they do not have metabolic acidosis at baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium bicarbonate</intervention_name>
    <description>Sodium bicarbonate. See arms.</description>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with epilepsy receiving oral topiramate for a minimum of 3 months

        Exclusion Criteria:

          -  pre-existing renal impairments (ie nephropathy, primary nephritis)

          -  receiving other medications or diet therapies that may influence renal function or
             urine acidity/ citrate concentration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mandeep Sidhu, MD</last_name>
    <phone>19055212100</phone>
    <phone_ext>6924</phone_ext>
    <email>mandeep.sidhu@medportal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Surejini Tharmaradinam, MD</last_name>
    <phone>19055212100</phone>
    <phone_ext>6760</phone_ext>
    <email>surejini.tharmaradinam@medportal.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mandeep Sidhu, MD</last_name>
      <phone>9055212100</phone>
      <phone_ext>6924</phone_ext>
      <email>mandeep.sidhu@medportal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Surejini Tharmaradinam, MD</last_name>
      <phone>9055212100</phone>
      <phone_ext>6760</phone_ext>
      <email>surejini.tharmaradinam@medportal.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Vladimir Belostotsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brandon Meaney, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Ben-Menachem E, Sander JW, Stefan H, Schwalen S, Sch√§uble B. Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy. Clin Ther. 2008 Jul;30(7):1180-95. Review.</citation>
    <PMID>18691980</PMID>
  </reference>
  <reference>
    <citation>Caudarella R, Vescini F. Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment. Arch Ital Urol Androl. 2009 Sep;81(3):182-7. Review.</citation>
    <PMID>19911682</PMID>
  </reference>
  <reference>
    <citation>Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest. 2005 Oct;115(10):2598-608. Review.</citation>
    <PMID>16200192</PMID>
  </reference>
  <reference>
    <citation>Dell'Orto VG, Belotti EA, Goeggel-Simonetti B, Simonetti GD, Ramelli GP, Bianchetti MG, Lava SA. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. Br J Clin Pharmacol. 2014 Jun;77(6):958-64. doi: 10.1111/bcp.12283. Review.</citation>
    <PMID>24219102</PMID>
  </reference>
  <reference>
    <citation>Hall PM. Nephrolithiasis: treatment, causes, and prevention. Cleve Clin J Med. 2009 Oct;76(10):583-91. doi: 10.3949/ccjm.76a.09043. Review.</citation>
    <PMID>19797458</PMID>
  </reference>
  <reference>
    <citation>HANLEY T, PLATTS MM. Observations on the metabolic effects of the carbonic anhydrase inhibitor diamox: mode and rate of recovery from the drug's action. J Clin Invest. 1956 Jan;35(1):20-30.</citation>
    <PMID>13278397</PMID>
  </reference>
  <reference>
    <citation>Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: extent, mechanism and effects. Br J Clin Pharmacol. 2009 Nov;68(5):655-61. doi: 10.1111/j.1365-2125.2009.03521.x.</citation>
    <PMID>19916989</PMID>
  </reference>
  <reference>
    <citation>Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009 Aug 18;151(4):264-9, W64. Epub 2009 Jul 20.</citation>
    <PMID>19622511</PMID>
  </reference>
  <reference>
    <citation>Silberstein SD, Ben-Menachem E, Shank RP, Wiegand F. Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther. 2005 Feb;27(2):154-65. Review.</citation>
    <PMID>15811478</PMID>
  </reference>
  <reference>
    <citation>Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf. 2007 Sep;6(5):547-57. Review.</citation>
    <PMID>17877442</PMID>
  </reference>
  <reference>
    <citation>Wile D. Diuretics: a review. Ann Clin Biochem. 2012 Sep;49(Pt 5):419-31. doi: 10.1258/acb.2011.011281. Epub 2012 Jul 10. Review.</citation>
    <PMID>22783025</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2017</study_first_posted>
  <last_update_submitted>November 24, 2017</last_update_submitted>
  <last_update_submitted_qc>November 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster Children's Hospital</investigator_affiliation>
    <investigator_full_name>Mandeep Sidhu</investigator_full_name>
    <investigator_title>Resident Physician</investigator_title>
  </responsible_party>
  <keyword>topiramate</keyword>
  <keyword>epilepsy</keyword>
  <keyword>sodium bicarbonate</keyword>
  <keyword>urine alkalinization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Acidosis, Renal Tubular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

